2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
442
Rectal Neoplasms
209
Colonic Neoplasms
202
Pancreatic Neoplasms
133
Stomach Neoplasms
117
Neoplasm Metastasis
97
Neoplasms
64
Esophageal Neoplasms
57
Precursor Cell Lymphoblastic Leukemia-Lymphoma
51
Lymphoma
49
Leukemia
41
Carcinoma, Hepatocellular
41
Adenocarcinoma Of Esophagus
37
Burkitt Lymphoma
33
Adenocarcinoma
29
Cholangiocarcinoma
27
Biliary Tract Neoplasms
23
Carcinoma, Non-Small-Cell Lung
21
Gastrointestinal Neoplasms
20
Gallbladder Neoplasms
20
Lymphoma, Non-Hodgkin
19
Esophageal Squamous Cell Carcinoma
15
Osteosarcoma
14
Liver Neoplasms
14
Bile Duct Neoplasms
14
Unspecified Adult Solid Tumor, Protocol Specific
13
Lymphoma, Large B-Cell, Diffuse
13
Leukemia, Biphenotypic, Acute
13
Ovarian Neoplasms
12
Leukemia, Myeloid, Acute
12
Interventions
Lenalidomide
4
Gemcitabine
4
Dexamethasone
4
Cyclophosphamide
4
Bortezomib
4
Nivolumab
3
Cisplatin
3
Carboplatin
3
vandetanib
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
pomalidomide
2
pembrolizumab
2
liposomal doxorubicin
2
fludarabine
2
durvalumab
2
capivasertib
2
Radiosurgery
2
Paclitaxel
2
Doxorubicin
2
Bevacizumab
2
Anthropogenic Effects
2
venetoclax
1
umbralisib
1
ublituximab
1
tremelimumab
1
tivozanib
1
ricolinostat
1
regorafenib
1
pazopanib
1
niraparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Leucovorin
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts